Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib in scleroderma-related interstitial lung disease
NCT04837131Phase 2Terminated
- Start
- Apr 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib in systemic sclerosis (SSc), interstitial lung disease (ILD). Started Apr 2021; status: terminated.
02
Drugs
ixazomib
03
Conditions
systemic sclerosis (SSc)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT04837131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04837131.